Nyrada, Inc. · ASX:NYR
Nyrada — Shareholder Meeting (November 2021)
22 slides from Nyrada's shareholder meeting presentation, Nov 19, 2021
Slide 1: Annual General Meeting Presentation
For personal use only Annual General Meeting Presentation James Bonnar Chief Executive Officer 19 November 2021│Sydney NSW NYRADA INC (ASX:NYR) Authorised by Mr. John Moore, Non-Executive 1 Chairman, on behalf of the Board. AGM PRESENTATION
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should Although the Company believes that the expectations reflected in the forward-looking not be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 3: Company Overview
Company Overview For personal use only • Drug discoverer and early-stage developer • Two lead drug development programs with significant therapeutic and commercial potential: • Cholesterol-Lowering Program • Brain Injury Program • Lead drug development programs funded through Phase I • Collaboration
Slide 4: Vision & Strategy
Vision & Strategy For personal use only • To improve lives and offer hope through innovation • We aim to deliver novel treatments for diseases where: • There is an unmet clinical need; or • Current treatments are suboptimal Our strategy is to advance highly optimised drug candidates towards a key va
Slide 5: Cholesterol-Lowering Program
For personal use only Cholesterol-Lowering Program ASX:NYR NYRADA INC (ASX:NYR) 5 AGM PRESENTATION
Slide 6: High LDL Cholesterol and Cardiovascular Disease (CVD)
High LDL Cholesterol and Cardiovascular Disease (CVD) Problem and key statistics For personal use only High LDL cholesterol CVD responsible for Healthcare costs for CVD a leading cause of CVD 1 in 4 deaths ~US$363B/year (US)1 Statins are suboptimal for 70% of patients and often poorly tolerated 62M
Slide 7: Current PCSK9 inhibitors
Current PCSK9 inhibitors For personal use only ✓ Effective as a single treatment or combined with a statin × Expensive (~US$5,800/year) and require 2-4 weekly injections • Amgen and Sanofi/Regeneron reduced the price of their injectable PCSK9 inhibitors, Repatha® (evolocumab) and Praluent® (alirocum
Slide 8: Nyrada's Program
Nyrada’s Program For personal use only • We are developing an oral PCSK9 inhibitor drug (taken as a pill) for the treatment of high LDL (bad) cholesterol levels in patients at risk of cardiovascular disease • Nyrada’s drug would replace expensive and inconvenient injectable PCSK9 inhibitor drugs and
Slide 9: Program Milestones – FY2021 & FY2022
Program Milestones – FY2021 & FY2022 For personal use only Medicinal chemistry program reveals new potent drug NYX-PCSK9i NYX-PCSK9i shows candidates mechanism of action 57% reduction in total confirmed by cholesterol1 increased plasma Mid July Jan June July PCSK9 levels1 CY 2020 2021 2021 2021 2022
Slide 10: Brain Injury Program
For personal use only Brain Injury Program ASX:NYR NYRADA INC (ASX:NYR) 10 AGM PRESENTATION
Slide 11: Global Market with Large Unmet Need - Brain Injury After TBI or Stroke
Global Market with Large Unmet Need - Brain Injury After TBI or Stroke For personal use only Nyrada is developing a neuroprotectant drug to reduce the impact of secondary brain injury in patients following a stroke or traumatic brain injury (TBI), which can occur following a motor vehicle accident,
Slide 12: Reducing Secondary Brain Injury After TBI or Stroke
Reducing Secondary Brain Injury After TBI or Stroke First-ever drug to improve survivability and patient quality of life For personal use only • Treatment for secondary brain injury following TBI or Stroke • Administered intravenously (TBI and Stroke) or intranasally Primary Secondary Disability Inj
Slide 13: Program Milestones – FY2021 & FY2022
Program Milestones – FY2021 & FY2022 For personal use only Pilot work commenced to Pilot study Collaboration determine the baseline End 2H July evaluating the secured with June injury signal in TBI animal CY CY 2020 intranasal route 2021 WRAIR and models that are expected of delivery for 2021 2022 U
Slide 14: For personal use only
For personal use only Corporate Update ASX:NYR NYRADA INC (ASX:NYR) 14 AGM PRESENTATION
Slide 15: FY2021 Financial Performance
FY2021 Financial Performance For personal use only Highlights • Nyrada ended FY2021 with cash of $13.8M Operating Results Summary • Cash position as at the end of Q1 FY2022 was $12.4M FY2021 (A$) FY2020 (A$) • R&D Tax Incentive refund of $2.3M relating to the accrued FY2021 refund of $1.3M and recei
Slide 16: Strong Intellectual Property Position
Strong Intellectual Property Position For personal use only • In July 2021, the US Patent & Trademark Office granted Nyrada’s first patent for the Cholesterol- Lowering Program’s PCSK9i inhibitor, with an expiry date of 16 March 2038 • The composition of matter patent protects Nyrada’s intellectual
Slide 17: COVID Update
COVID Update For personal use only • No significant impact on operations despite multiple government mandated COVID-19 lockdowns in Sydney and Melbourne • Successfully transitioned to remote working model • Team appreciate greater flexibility, leading to enhanced productivity and morale • Remote wor
Slide 18: Scientific Advisory Board
Scientific Advisory Board For personal use only Professor Gary Housley Professor David Burke Professor Gilles Lambert Professor Junichi Dr. Jim Palmer Chair, M.Sc Ph.D MD, DSc, AC Ph.D Nabekura, Ph.D Ph.D Chair in Physiology (UNSW) Professor of Neurology Professor in Cell Biology at Professor of Phy
Slide 19: Key Metrics & Timing of Phase I Studies
Key Metrics & Timing of Phase I Studies For personal use only Market capitalisation 1H 2H $36.6M Program Pathways to Phase I (as at 18 November 2021) CY2022 CY2022 Share price Cholesterol-Lowering Program $0.235 Expect to enter clinic following completion of (as at 18 November 2021) preclinical stud
Slide 20: Reporting on Program Milestones
Reporting on Program Milestones Anticipated upcoming news flow For personal use only Cholesterol-Lowering • Anticipated completion of safety pharmacology • Mid-CY2022 Program and toxicology studies expected mid-CY2022 • Phase I first in human studies to follow once preclinical studies are complete (
Slide 21: Questions?
For personal use only Questions? Brain Injury Solution Cholesterol-Lowering Animation Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 21 AGM PRESENTATION
Slide 22: www.nyrada.com
For personal use only www.nyrada.com NYRADA INC (ASX:NYR) 22 AGM PRESENTATION